 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...2324252627282930313233...266267» |
- Opdivo (nivolumab) / Ono Pharma, BMS, Sutent (sunitinib) / Pfizer, Yervoy (ipilimumab) / Ono Pharma, BMS
Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial. (Level 3, Ballroom) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_161;
P3
CR rates were higher and median DOR was longer with NIVO+IPI vs SUN regardless of IMDC risk group, and in LTS pts. No new safety signals emerged.
- Opdivo (nivolumab) / Ono Pharma, BMS
Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial. (Level 3, Ballroom) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_138;
P3
Safety of NIVO monotherapy was consistent with its known profile in advanced RCC. Clinical trial information: NCT03138512.
- ||| Clinical, Retrospective data, Review, Journal, Adverse events, Checkpoint inhibition: Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors: A systematic review and network meta-analysis. (Pubmed Central) - Dec 13, 2023
Regarding severe TRAEs and IRAEs, nivolumab and atezolizumab are likely to be the safest agent, respectively. This study will guide clinical practice for ICI adjuvant therapies.
- | troriluzole (BHV-4157) / Biohaven, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets (clinicaltrials.gov) - Dec 13, 2023
P2, N=1, Terminated, Sponsor: Dana-Farber Cancer Institute
This study will guide clinical practice for ICI adjuvant therapies. N=108 --> 1 | Trial completion date: Nov 2025 --> May 2023 | Suspended --> Terminated | Trial primary completion date: Nov 2024 --> May 2023; Due to poor enrollment
- ||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Tumor mutational burden, IO biomarker: CA224-056: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer (clinicaltrials.gov) - Dec 12, 2023
P2, N=80, Recruiting, Sponsor: Robert L. Ferris, MD, PhD
N=108 --> 1 | Trial completion date: Nov 2025 --> May 2023 | Suspended --> Terminated | Trial primary completion date: Nov 2024 --> May 2023; Due to poor enrollment N=60 --> 80
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion: Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 12, 2023
P2, N=30, Completed, Sponsor: Kristen Ganjoo
N=60 --> 80 Active, not recruiting --> Completed
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Tumor Infiltrating Lymphocytes (TILs) Therapy () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1089;
Proper patient selection is important. Multidisciplinary team that can manage complications affecting virtually any organ is important for performing TILs.
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal: Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement. (Pubmed Central) - Dec 11, 2023
Future clinical studies aim to rebiopsy patients after disease progression to identify new molecular alterations and to be associated with ancillary studies, guiding subsequent therapy decisions. Predicting and investigating treatment resistance mechanisms will lead to innovative approaches and improved treatment outcomes.
- | Journal, Checkpoint inhibition, Metastases: Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. (Pubmed Central) - Dec 11, 2023
Immune checkpoint inhibitors are active in a subset of patients with penile squamous cell carcinoma. Future translational studies are warranted to identify patients more likely to derive clinical benefit from immune checkpoint inhibitors.
- || Avastin (bevacizumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal: Good Gone Bad: Complications of Chemotherapy, Immunotherapy, and Radiotherapy on the CNS. (Pubmed Central) - Dec 11, 2023
Immunotherapy complications included are Tacrolimus-related Optic Neuropathy, Rituximab and Immune reconstitution inflammatory syndrome-associated Progressive Multifocal Leukoencephalopathy, Bevacizumab-associated late radiation-induced neurotoxicity, and Ipilimumab-induced hypophysitis...Neuroradiologists will increasingly encounter patients who have undergone treatment with more than 1 therapeutic modality, resulting in overlapping findings as well. Recognition of the common complications of these therapies on imaging is critical to minimizing the effects of these potential short- and long-term complications.
- | Avastin (bevacizumab) / Roche
New P1/2 trial, Checkpoint inhibition, IO biomarker: BETTER: Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases (clinicaltrials.gov) - Dec 11, 2023
P1/2, N=46, Not yet recruiting, Sponsor: Melanoma and Skin Cancer Trials Limited
- | Journal, Checkpoint inhibition: Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs. (Pubmed Central) - Dec 9, 2023
Using Patlak analysis and the established ns-baseline values, evidence for target engagement in (lymphoid) organs for several immune checkpoint inhibitors could be demonstrated. A decrease in the K values with increasing mass doses supports the applicability of Patlak analysis for the assessment of target engagement for PET ligands with irreversible uptake behavior.
- |||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New trial, HEOR, Monotherapy, Real-world evidence: CA209-1068: A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma (clinicaltrials.gov) - Dec 8, 2023
P=N/A, N=100, Completed, Sponsor: Bristol-Myers Squibb
- |||||| volrustomig (MEDI5752) / AstraZeneca
Enrollment open: eVOLVE-Meso: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (clinicaltrials.gov) - Dec 8, 2023
P3, N=600, Recruiting, Sponsor: AstraZeneca
A decrease in the K values with increasing mass doses supports the applicability of Patlak analysis for the assessment of target engagement for PET ligands with irreversible uptake behavior. Not yet recruiting --> Recruiting
- | LMB-100 / National Cancer Institute
Trial completion, Enrollment change: Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma (clinicaltrials.gov) - Dec 7, 2023
P1, N=2, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Completed | N=20 --> 2
- | Trial completion date, Trial primary completion date: DREAMseq: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (clinicaltrials.gov) - Dec 7, 2023
P3, N=300, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=20 --> 2 Trial completion date: Oct 2024 --> Jun 2024 | Trial primary completion date: Oct 2024 --> Jun 2024
- | Trial completion date, Trial primary completion date, Surgery, Metastases: Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 7, 2023
P2, N=168, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2024 --> Jun 2024 | Trial primary completion date: Oct 2024 --> Jun 2024 Trial completion date: Dec 2024 --> Mar 2024 | Trial primary completion date: Dec 2024 --> Mar 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: EA2174: Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery (clinicaltrials.gov) - Dec 6, 2023
P2/3, N=278, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2024 --> Mar 2024 | Trial primary completion date: Dec 2024 --> Mar 2024 Trial completion date: Dec 2023 --> Jan 2026 | Trial primary completion date: Dec 2023 --> Jan 2026
- Jemperli (dostarlimab-gxly) / GSK, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Short course immunotherapy as curative-intent treatment in stage I-III dMMR rectal cancer. (Level 1, West Hall; Poster Bd # H6) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_767;
Clinical trial information: 2022-500646-14-00. >cCR = clinical complete response, pCR = pathological complete response, rCR = radiological complete response.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142. (Level 1, West Hall; Poster Bd # F20) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_743;
P2
Safety remained consistent with previous data. These findings further support current recommendations for NIVO + IPI as a 1L treatment for pts with MSI-H/dMMR mCRC.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Changes in circulating immune biomarkers following nivolumab with or without ipilimumab for metastatic anal cancer (NCI9673). (Level 1, West Hall; Poster Bd #: B13) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_659;
These data not only implicate T and NK cells in mediating treatment effect following single agent and/or combination immunotherapy, but also support the exploration of TIGIT as a potential novel target for treatment of metastatic SCCA. >
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable hepatocellular carcinoma. (Poster Bd # G9) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_500;
Our data show that large baseline tumor size, greater OR, reduction in AFP, increase in liver and tumor fibrosis, and increase in CD8, Granzyme B, and PD-1 expression after receipt of neoadjuvant immunotherapy are associated with achieving an MPR in patients with resectable HCC. >
- Voyager-V1 / Vyriad, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-? and NIS (VSV-IFN?-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma. (Poster Bd # P18) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_367;
P1/2
The optimal systemic therapy beyond first line platinum and etoposide is not established...If at least one objective response is observed, and safety is confirmed, the regimen will be considered for future study. Clinical trial information: NCT03647163.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
SBRT with ipilimumab and nivolumab to metastatic MSS colorectal and pancreatic cancer: A pooled analysis of four prospective phase II trials. (Poster Bd # M7) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_324;
P2
Ablative SBRT dosing yielded a significantly higher depth of response. As clinical and preclinical studies suggest liver metastases are less responsive to IO, understanding dose and fractionation schemas for optimal local control is critical.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Initial findings from the DREAM-GI national database: Assessing the efficacy and safety of neoadjuvant immunotherapy (NIT) in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastrointestinal (GI) cancer. (Poster Bd # L11) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_309;
Progression on NIT was infrequent. These real-world data support further investigation into non-operative approaches for patients with dMMR/MSI-H GI cancers.
- Opdivo (nivolumab) / Ono Pharma, BMS
Relationship between the number of positive MSI markers and the efficacy of NIVO+IPI therapy in MSI-H gastric cancer: A subgroup analysis of NO LIMIT study (WJOG13320G/CA209-7W7). (Poster Bd # J9) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_269;
Further follow-up is needed to confirm the relationship between survival. 1.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
The overall safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma. (Poster Bd # F9) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_213;
Our study may demonstrate a consistent incident of irAEs in pts who received Nivo+Ipi in the real world, compared to the results of the CheckMate 648. Despite of the short time of follow-up period, 1st-line treatment with Nivo+Ipi appeared to be more efficacious than Nivo+Ipi used as a later-line treatment.
- Opdivo (nivolumab) / Ono Pharma, BMS
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up. (Poster Bd # E18) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_202;
P3
These results are consistent with previous reports and with the overall study population with advanced GC/GEJC/EAC and further support NIVO + chemo as a standard 1L treatment option for Chinese pts. Clinical trial information: NCT02872116.
- Opdivo (nivolumab) / Ono Pharma, BMS
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649. (Poster Bd # E6) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_190;
P3
These results are consistent with earlier follow-ups, further supporting NIVO + chemo as a standard 1L treatment in these pts. Clinical trial information: NCT02872116.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648. () - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_115;
P3
The clinical utility of these biomarkers should be validated in future trials. Clinical trial information: NCT03143153.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
A quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis comparing nivolumab plus ipilimumab (N+I) or nivolumab plus chemotherapy (N+CT) versus CT in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648. () - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_114;
P3
Quality-adjusted survival using Q-TWiST also significantly favored N+I and N+CT compared to CT alone. Pts treated with N+I and N+CT not only experienced increased survival time, but also better QoL during their survival time.
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Yervoy (ipilimumab) / BMS
Enrollment change, Trial completion date, Trial primary completion date, Metastases: CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Dec 6, 2023
P2, N=16, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Pts treated with N+I and N+CT not only experienced increased survival time, but also better QoL during their survival time. N=30 --> 16 | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
- | Opdivo (nivolumab) / BMS, Actemra SC (tocilizumab SC) / Roche, Halozyme, Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change: NCI-2021-04325: Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (clinicaltrials.gov) - Dec 6, 2023
P2, N=35, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=30 --> 16 | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025 Recruiting --> Active, not recruiting | N=55 --> 35
- ||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion: LIGHT-NING: A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan (clinicaltrials.gov) - Dec 6, 2023
P=N/A, N=525, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | N=55 --> 35 Recruiting --> Completed
- ||| HLX13 (ipilimumab biosimilar) / Fosun Pharma, Organon
New P1 trial: A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects (clinicaltrials.gov) - Dec 6, 2023
P1, N=304, Recruiting, Sponsor: Shanghai Henlius Biotech
- | Trial completion date, Trial primary completion date, Surgery, Metastases: Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 5, 2023
P2, N=168, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, PD(L)-1 Biomarker: Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. (Pubmed Central) - Dec 5, 2023
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Nivolumab plus ipilimumab did not meet prespecified criteria to declare a signal of activity in patients with solid tumors with ATM mutations.
- CIML NK - Dana / Farber Cancer Institute, Anktiva (inbakicept) / ImmunityBio, Yervoy (ipilimumab) / Ono Pharma, BMS
CTLA-4 Blockade Leads to Enrichment of Active CD56dimCD16+ NK Cells and Depletion of Regulatory T Cells Following Infusion of Haploidentical Donor Memory-like Natural Killer Cells Plus IL-15 Superagonist in a Phase 1 Trial (Stars at Night B2 & B3 (Ballroom Level, Henry B. Gonzalez Convention Center); in-person) - Dec 5, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_702;
P1
We, therefore, hypothesized the use of CTLA-4 blockade with ipilimumab (IPI) would deplete Tregs in vivo and thus allow enhanced proliferation, activation, and anti-tumor responses of the adoptively transferred CIML NK cells...All patients received lymphodepletion with fludarabine (25 mg/m2 x 5 days) and cyclophosphamide (60 mg/kg x 2 days) and haploidentical CIML NK cell infusion (5-10 x 106 cells/kg) followed by IL-15 superagonist (N-803) (15 mcg/kg subcutaneously) starting on day +1 every 21-days (4x)...The use of IPI was associated with a relative depletion of Tregs with concurrent expansion of CD56dimCD16+ NK cells that had enrichment of proliferative (MYC), metabolically active (mTORC1), and cytokine reactive (TNFa) gene sets. Further work is required to elucidate the mechanism by which IPI exposure is associated with the expansion of specific subsets of CIML NK cells.
- || Clinical data, Journal, Real-world evidence, Real-world, Metastases: Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab?+?axitinib vs. ipilimumab?+?nivolumab. (Pubmed Central) - Dec 5, 2023
Our study provides insight into newer mccRCC treatment tolerability and effectiveness in the real-world US community setting. Our real-world results were comparable to data from clinical trials, which is encouraging for mccRCC patients.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: A Recurrent Colon Cancer Successfully Treated by Nivolumab plus Ipilimumab with On and Off for Preventing Exacerbation of Skin Disorders (Pubmed Central) - Dec 5, 2023
Here, we report a case in which nivolumab plus ipilimumab combination therapy was significantly effective for MSI-high recurrent colon cancer with acute exacerbation after 5-FU/L-OHP/CPT-11 treatment...After the resumption of treatment, an increase in eosinophils and worsening of skin symptoms were observed again, and stopped treatment. We report an interesting case in which immune checkpoint inhibiter were turned on and off according to eosinophil counts for preventing exacerbation of skin disorders, and for maintaining cancer remission by continuing immune checkpoint inhibitor treatment.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB. (Pubmed Central) - Dec 5, 2023
P2
We observed that tTMB and bTMB had a statistically significant correlation, particularly for samples with high MSAF, and that this correlation applied across disease ontologies. Further investigation into the clinical utility of bTMB is warranted.
- ||| temozolomide/perillyl alcohol conjugate (NEU001) / NeOnc Technologies, NeuCen BioMed
Enrollment open, IO biomarker: Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (clinicaltrials.gov) - Dec 5, 2023
P1/2, N=134, Recruiting, Sponsor: Neonc Technologies, Inc.
Further investigation into the clinical utility of bTMB is warranted. Not yet recruiting --> Recruiting
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: CA209-63Y: Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients (clinicaltrials.gov) - Dec 4, 2023
P1/2, N=46, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting .
- | Journal: Lack of observed interference by therapeutic monoclonal antibodies in select commonly utilized immunoassays. (Pubmed Central) - Dec 4, 2023
These findings demonstrate no detectable tmab interference for the assessed immunoassays using spiked preparations of the tmabs in residual human sera. The findings are limited to the tmabs and immunoassays studied here.
- | Opdivo (nivolumab) / Ono Pharma, BMS, vidutolimod (CMP-001) / Regeneron, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Surgery: Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases. (Pubmed Central) - Dec 4, 2023
The combination of intratumoral vidutolimod, radiosurgery, nivolumab and ipilimumab was not found to be efficacious in MSS mCRC with liver metastases. The juxtaposition of liver irradiation and intratumoral vidutolimod injection was associated with high hepatic toxicity.
- | Journal, Checkpoint inhibition: Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. (Pubmed Central) - Dec 4, 2023
Nephrectomy following ICI therapy is feasible and a potential consolidative therapy option in select patients. Further research in the neoadjuvant setting is also warranted.
- | Opdivo (nivolumab) / BMS, Cabometyx (cabozantinib tablet) / Exelixis, Yervoy (ipilimumab) / BMS
Trial initiation date, Tumor mutational burden, IO biomarker: Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 4, 2023
P2, N=66, Recruiting, Sponsor: National Cancer Institute (NCI)
Further research in the neoadjuvant setting is also warranted. Initiation date: Jun 2024 --> Oct 2023
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Trial initiation date: Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (clinicaltrials.gov) - Dec 4, 2023
P1/2, N=16, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jun 2024 --> Oct 2023 Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Aug 2024
- | Tafinlar (dabrafenib) / Novartis, BeiGene, Zelboraf (vemurafenib) / Roche, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: From a mutation to a drug (Pubmed Central) - Dec 3, 2023
Then we provide information about other popular drugs for malignant melanoma, i.e. dacarbazine, ipilimumab and dabrafenib, and about the advantages of therapy with the simultaneous use of two inhibitors. Finally, we briefly discuss the role of artificial intelligence in the future of drug design.
- | Entyvio (vedolizumab) / Takeda
Journal, Combination therapy, Checkpoint inhibition: A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte-monocyte apheresis combination therapy. (Pubmed Central) - Dec 2, 2023
A 68-year-old man developed immune-related adverse event (irAE) colitis after the initiation of nivolumab and ipilimumab combination therapy for malignant melanoma...Therefore, we started infliximab (IFX)...Twelve weeks after the onset, the colitis was in remission. Therefore, in addition to vedolizumab, GMA may be considered in cases refractory to treatment.